Compare Abeona Therapeutics Inc (ABEO) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global Payments Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Global Payments Inc trades at $73.2 (market cap $21.22B). The key difference: Global Payments Inc is far larger — about 56.8× Abeona Therapeutics Inc's market cap, and Global Payments Inc pays a 1.29% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GPN | |
|---|---|---|
Market Cap | $373.32M | $21.22B |
Sector | Health | Industrials |
52-Week High | $7.23 | $90.01 |
52-Week Low | $4.17 | $62.47 |
Enterprise Value | $228.22M | $38.94B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GPN trades at $77.59, down 1.32% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.96 exceeding expectations. Revenue for 2025 was $7.71 billion, though net income margin turned negative at -7.97% for 2026 projections. Analysts maintain a buy consensus with a $80 price target, citing growth from the Worldpay integration and new AI-powered POS launches.
The stock presents a mixed outlook: positive analyst sentiment and strategic expansions support upside, but margin pressures and rising debt pose risks. Investors should weigh the company's innovation against competitive fintech threats and macroeconomic headwinds affecting transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
